These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 25935551)

  • 1. Monitoring of Hepatitis B Virus (HBV) DNA and Risk of HBV Reactivation in B-Cell Lymphoma: A Prospective Observational Study.
    Kusumoto S; Tanaka Y; Suzuki R; Watanabe T; Nakata M; Takasaki H; Fukushima N; Fukushima T; Moriuchi Y; Itoh K; Nosaka K; Choi I; Sawa M; Okamoto R; Tsujimura H; Uchida T; Suzuki S; Okamoto M; Takahashi T; Sugiura I; Onishi Y; Kohri M; Yoshida S; Sakai R; Kojima M; Takahashi H; Tomita A; Maruyama D; Atsuta Y; Tanaka E; Suzuki T; Kinoshita T; Ogura M; Mizokami M; Ueda R
    Clin Infect Dis; 2015 Sep; 61(5):719-29. PubMed ID: 25935551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma.
    Cho Y; Yu SJ; Cho EJ; Lee JH; Kim TM; Heo DS; Kim YJ; Yoon JH
    J Med Virol; 2016 Jun; 88(6):1010-7. PubMed ID: 26531242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy.
    Kusumoto S; Arcaini L; Hong X; Jin J; Kim WS; Kwong YL; Peters MG; Tanaka Y; Zelenetz AD; Kuriki H; Fingerle-Rowson G; Nielsen T; Ueda E; Piper-Lepoutre H; Sellam G; Tobinai K
    Blood; 2019 Jan; 133(2):137-146. PubMed ID: 30341058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study.
    Seto WK; Chan TS; Hwang YY; Wong DK; Fung J; Liu KS; Gill H; Lam YF; Lie AK; Lai CL; Kwong YL; Yuen MF
    J Clin Oncol; 2014 Nov; 32(33):3736-43. PubMed ID: 25287829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group.
    Kim SJ; Hsu C; Song YQ; Tay K; Hong XN; Cao J; Kim JS; Eom HS; Lee JH; Zhu J; Chang KM; Reksodiputro AH; Tan D; Goh YT; Lee J; Intragumtornchai T; Chng WJ; Cheng AL; Lim ST; Suh C; Kwong YL; Kim WS
    Eur J Cancer; 2013 Nov; 49(16):3486-96. PubMed ID: 23910494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection.
    Yang HC; Tsou HH; Pei SN; Chang CS; Chen JH; Yao M; Lin SJ; Lin J; Yuan Q; Xia N; Liu TW; Chen PJ; Cheng AL; Hsu C;
    J Hepatol; 2018 Aug; 69(2):286-292. PubMed ID: 29551710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential risk of HBV reactivation in patients with resolved HBV infection undergoing direct-acting antiviral treatment for HCV.
    Ogawa E; Furusyo N; Murata M; Toyoda K; Hayashi T; Ura K
    Liver Int; 2018 Jan; 38(1):76-83. PubMed ID: 28618152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma.
    Matsue K; Kimura S; Takanashi Y; Iwama K; Fujiwara H; Yamakura M; Takeuchi M
    Cancer; 2010 Oct; 116(20):4769-76. PubMed ID: 20597091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
    Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
    Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reactivation of hepatitis B virus in patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma.
    Matsui T; Kang JH; Nojima M; Tomonari A; Aoki H; Yamazaki H; Yane K; Tsuji K; Andoh S; Andoh S; Sakai H; Maemori M; Maguchi H; Tanaka Y
    J Med Virol; 2013 Nov; 85(11):1900-6. PubMed ID: 23926082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for and management of hepatitis B virus reactivation in patients treated with anti-B-cell therapy.
    Kusumoto S; Tobinai K
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):576-83. PubMed ID: 25696914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective long-term study of hepatitis B virus reactivation in patients with hematologic malignancy.
    Tamori A; Hino M; Kawamura E; Fujii H; Uchida-Kobayashi S; Morikawa H; Nakamae H; Enomoto M; Murakami Y; Kawada N
    J Gastroenterol Hepatol; 2014 Sep; 29(9):1715-21. PubMed ID: 24730465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy.
    Kusumoto S; Tanaka Y; Ueda R; Mizokami M
    J Gastroenterol; 2011 Jan; 46(1):9-16. PubMed ID: 20924616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Latest Treatment of Viral Hepatitis--Overcoming Hepatitis C and Reactivation of Hepatitis B].
    Tanaka Y
    Rinsho Byori; 2016 Feb; 64(2):211-8. PubMed ID: 27311286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.
    Huang YH; Hsiao LT; Hong YC; Chiou TJ; Yu YB; Gau JP; Liu CY; Yang MH; Tzeng CH; Lee PC; Lin HC; Lee SD
    J Clin Oncol; 2013 Aug; 31(22):2765-72. PubMed ID: 23775967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ultra-high sensitivity HBsAg assay can diagnose HBV reactivation following rituximab-based therapy in patients with lymphoma.
    Kusumoto S; Tanaka Y; Suzuki R; Watanabe T; Nakata M; Sakai R; Fukushima N; Fukushima T; Moriuchi Y; Itoh K; Nosaka K; Choi I; Sawa M; Okamoto R; Tsujimura H; Uchida T; Suzuki S; Okamoto M; Takahashi T; Sugiura I; Onishi Y; Kohri M; Yoshida S; Kojima M; Takahashi H; Tomita A; Atsuta Y; Maruyama D; Tanaka E; Suzuki T; Kinoshita T; Ogura M; Ueda R; Mizokami M
    J Hepatol; 2020 Aug; 73(2):285-293. PubMed ID: 32194183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.
    Dai MS; Chao TY; Kao WY; Shyu RY; Liu TM
    Ann Hematol; 2004 Dec; 83(12):769-74. PubMed ID: 15338194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
    Yeo W; Chan TC; Leung NW; Lam WY; Mo FK; Chu MT; Chan HL; Hui EP; Lei KI; Mok TS; Chan PK
    J Clin Oncol; 2009 Feb; 27(4):605-11. PubMed ID: 19075267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significant rate of hepatitis B reactivation following kidney transplantation in patients with resolved infection.
    Kanaan N; Kabamba B; Maréchal C; Pirson Y; Beguin C; Goffin E; Hassoun Z
    J Clin Virol; 2012 Nov; 55(3):233-8. PubMed ID: 22921412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.
    Law MF; Ho R; Cheung CK; Tam LH; Ma K; So KC; Ip B; So J; Lai J; Ng J; Tam TH
    World J Gastroenterol; 2016 Jul; 22(28):6484-500. PubMed ID: 27605883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.